NCT07281300Active, not recruiting
Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer
Mindfulness-Oriented Respiratory Distress Symptom Intervention for Patients With Lung Cancer: A Feasibility Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
Lung cancer is the leading cause of cancer mortality, posing a critical public health challenge in both Hong Kong and global populations. Patients with lung cancer frequently experience a distressing symptom cluster characterized by breathlessness-driven respiratory distress, accompanied by persistent cough and fatigue, which collectively impose a substantial disease burden. While our research team leader previously developed and validated a multi-component Respiratory Distress Symptom Intervention (RDSI) in England, demonstrating clinical efficacy for lung cancer management, its impact on psychological distress (anxiety and depression) proved limited. This limitation may reflect insufficient integration of psychological components, a crucial consideration given the well-established bidirectional relationship between respiratory symptoms and psychological distress. Emerging evidence indicates that mindfulness interventions provide dual therapeutic benefits by improving patient adherence and effectively addressing both physical symptoms, such as breathlessness and fatigue, as well as psychological distress, including anxiety and depression. Meanwhile, current evaluation methodologies have mainly focused on behavioral data collection, such as self-reported questionnaires, to reflect the effect before and after the intervention. Neuroimaging data can help understand the brain mechanisms underlying breathlessness and elucidate the effectiveness of interventions, thereby improving intervention strategies.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 5 Jun 2025
- Start date
- 12 Aug 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- The Hong Kong Polytechnic University
- Diseases
- Lung cancer
- NCT number
- NCT07281300
What you commit to
- Study type: Interventional
- Participants enrolled: 70
- From 12 Aug 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cognitive impairments, severe psychotic symptoms, or other medical conditions that might hinder participation;
Other
- Participating in mindfulness or other psychological support interventions or symptom management interventions.
Who the study is looking for
- HK patients who can understand Cantonese, aged 18 years or older;
- A confirmed diagnosis of an intrathoracic malignancy, including small cell lung cancer, non-small cell lung cancer, or mesothelioma; at any stage of cancer treatment or palliative care;
- Self-reported impact on daily life from at least two of the three symptoms, where one symptom is breathlessness;
- Stability of COPD, if present;
- WHO Performance Status of 0-2;
- fMRI can be conducted;
- Expected lifespan of more than six months.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Hong Kong Polytechnic University Coordinator of this site? Confirm its status | Hong Kong | Hong Kong | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.